Post by
geodcan on Jan 01, 2023 6:29pm
Pressure is mounting
to get the US legislators to shyt or get off the pot on the marijuana issue and the cbd and hemp.
Now they are defining different cannabinoids that are crossing the line of psychoactive or non-psychoactive and it is something that needs to be dealt with.
The general school of thought is that anything that comes from hemp won't get you a psychoactive experience and they have even put in loopholes allowing hemp products even though the basics of hemp and marijuana are thc and cbd just in differing strengths.
I know people that overdo it on the cbd and they get high just like thc strains.
They could simply put it in two classes of psychoactive or non-psychoactive and that would solve the problem but then they have to wind up and reverse all of the bad legislation that they have introduced by mistake.
Investigation in the US has been difficult for pharma and effect determination because until recently you couldn't transport from the grow to the lab where they wanted to study the effects of different strains and such. It was even worse just prior to that because you could only get an inferior brand from one university who had the license to provide pot for the purpose of exploring the effects.
Most serious players in the US went out of the US to find alternate benefits with pharma use in mind.
All of the confusion is either by design or inability to straighten it out, possibly because the US has created a clusterfuch.
Canopy has made their intentions clear that they have the US in the crosshairs and are willing to forgo the Fed decriminalization to hurry up their US launch, I believe that they are willing to rely on the handshake deal that the Feds have announced that they will let pro legal pot States administer their own justice.
This announcement should have got more press than it did and done more for the shareprice of Canopy but make no mistake that Constellation has been solidly building for profits in the US.
Several of the investments made with US MSOs or individual like minded companies will make Canopy or whatever name it relaunches under a formidable player and number one contender but law and policy makers need to clear up the confusion and the best way to do that is to listen to the lobbyists that represent these companies.
US players should welcome the LPs and others for the betterment of the industry as a whole and the politicians need to deliver on what the voters want.
Personally, I have put my money where my mouth is, hoping that Constellation will bring their moneymaking and management expertise to Canopy and related companies to continue to be a leader in the cannabinoid business.
Twice we hit the $70C range and Canopy is plugging the drain in Canada and focusing on the US where MSOs have been able to show black ink. Acreage is the US MSO choice, already paid for option for rapid US expansion for Canopy.
I believe that Constellation will make this happen and continue to finance their first $5 billion C investment because they have a huge chance of success for what they have done and continue to do to be the world leader.
glta and dyodd
Comment by
TheGrapeOne on Jan 02, 2023 2:44pm
It would be easy if such a link exsists I get the feeling this is more FUD being spread